Global quality of life: Pharmacological interventions

Antidepressants

Four RCTs in women after breast cancer found no statistically significant effects on global quality of life between the SSRI and atypical antidepressants bupropion (300mg/d for 4 weeks, with a moderate risk of bias);29fluoxetine (20mg/d for 4 weeks, with a low risk of bias);15paroxetine (10mg/d for 4 weeks, with a low risk of bias);14 and sertraline (50mg/d for 6 weeks, with a moderate risk of bias),16 compared with placebo.

Sedatives

One RCT (with a moderate risk of bias) in women after breast cancer found a statistically significant improvement in global quality of life for SSRI/SNRI augmented with zolpidem (10mg/d) compared with SSRI/SNRI augmented with placebo.30